Arimoclomol FDA Approval Status
Last updated by Judith Stewart, BPharm on June 10, 2020.
FDA Approved: No
Generic name: arimoclomol
Company: Orphazyme A/S
Treatment for: Niemann-Pick Disease
Arimoclomol is an investigational Heat-Shock Protein amplifier in development for the treatment of Niemann-Pick disease Type C (NPC).
Development timeline for arimoclomol
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.